68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers

What this Trial Is About

This research aims to assess how well 68Ga-NK224 positron emission tomographycomputed tomography PETCT can measure PD-L1 expression in primary and metastatic tumors in people with cancer. It compares PETCT imaging results with tissue analysis through histopathology to better understand tumor characteristics. The study focuses on adults diagnosed with malignant tumors and evaluates imaging technology for its diagnostic value. Each participant receives a single intravenous injection of the imaging agent 68Ga-NK224, followed by PETCT scans to capture images of tumors. Tumor uptake is measured using maximum and mean standardized uptake values SUVmax and SUVmean. The PD-L1 expression in the tumors is then confirmed by examining tissue samples. This evaluation helps compare the imaging results with actual tissue findings. Participants undergo the PETCT imaging and tissue analysis, with data collected to assess the agreement between imaging and histopathological results within 30 days. Researchers also evaluate variability in PD-L1 expression within and between tumors. Participants may be followed for up to 30 days to monitor outcomes. The study involves adults aged 18 to 90 years and includes patients with both newly diagnosed and previously treated cancers.

68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers